Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors

被引:16
作者
Chau, Kai-Yin [1 ]
Korlipara, L. V. Prasad [1 ]
Cooper, J. Mark [1 ]
Schapira, Anthony H. V. [1 ]
机构
[1] UCL, Inst Neurol, Univ Dept Clin Neurosci, London NW3 2PF, England
关键词
Parkinson's disease; Dopamine; Agonist; Neuroprotection; alpha-synuclein; SHSY-5Y cells; PRAMIPEXOLE PROTECTS; LIPID-PEROXIDATION; GLUTATHIONE SYSTEM; CELL-DEATH; ACTIVATION; NEUROPROTECTION; BROMOCRIPTINE; REDUCTION; DISEASE; STRESS;
D O I
10.1016/j.jns.2008.11.012
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Both genetic and environmental factors are thought to be involved in the aetiology of Parkinson's disease (PD). Oxidative damage, mitochondrial and proteasomal dysfunction, and inflammatory change are considered to participate in PD pathogenesis. Dopamine agonists are used in the symptomatic treatment of PD but attention has recently also been focussed on their potential for use in slowing disease progression. We have studied the protective actions of the D2 dopamine agonist cabergoline in toxin (paraquat) and genetic (wild-type and mutant [A53T] alpha-synuclein) models of PD using SHSY-5Y cells. Cabergoline increased glutathione content, reduced free radical production and caspase-3 activation, increased mitochondrial membrane potential and ameliorated cell death in SHSY-5Ycells exposed to paraquat and this action was inhibited in part by D2 receptor blockade. Cabergoline also reduced the toxicity of wild-type and mutant alpha-synuclein expression following paraquat exposure by similar mechanisms. These results confirm the protective action of cabergoline in reducing cell death in two separate genetic and environmental model systems of PD. (c) 2008 Published by Elsevier B.V.
引用
收藏
页码:44 / 53
页数:10
相关论文
共 26 条
[1]  
ASANUMA M, 1995, ARCH INT PHARMACOD T, V329, P221
[2]  
Cassarino DS, 1998, J NEUROCHEM, V71, P295
[3]   Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment [J].
Finotti, N ;
Castagna, L ;
Moretti, A ;
Marzatico, F .
PHARMACOLOGICAL RESEARCH, 2000, 42 (04) :287-291
[4]   Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine [J].
Gassen, M ;
Gross, A ;
Youdim, MBH .
MOVEMENT DISORDERS, 1998, 13 (02) :242-248
[5]   Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms [J].
Gu, M ;
Irvani, M ;
Cooper, JM ;
King, D ;
Jenner, P ;
Schapira, AHV .
JOURNAL OF NEUROCHEMISTRY, 2004, 91 (05) :1075-1081
[6]   Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist [J].
Iida, M ;
Miyazaki, I ;
Tanaka, K ;
Kabuto, H ;
Iwata-Ichikawa, E ;
Ogawa, N .
BRAIN RESEARCH, 1999, 838 (1-2) :51-59
[7]   Pramipexole protects against MPTP toxicity in non-human primates [J].
Iravani, MM ;
Haddon, CO ;
Cooper, JM ;
Jenner, P ;
Schapira, AH .
JOURNAL OF NEUROCHEMISTRY, 2006, 96 (05) :1315-1321
[8]   Inhibitory effects of talipexole and pramipexole on MPTP-Induced dopamine reduction in the striatum of C57BL/6N mice [J].
Kitamura, Y ;
Kohno, Y ;
Nakazawa, M ;
Nomura, Y .
JAPANESE JOURNAL OF PHARMACOLOGY, 1997, 74 (01) :51-57
[9]   Sensitization of neuronal cells to oxidative stress with mutated human α-synuclein [J].
Ko, LW ;
Mehta, ND ;
Farrer, M ;
Easson, C ;
Hussey, J ;
Yen, S ;
Hardy, J ;
Yen, SHC .
JOURNAL OF NEUROCHEMISTRY, 2000, 75 (06) :2546-2554
[10]   Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection [J].
Le, WD ;
Jankovic, J ;
Xie, W ;
Appel, SH .
JOURNAL OF NEURAL TRANSMISSION, 2000, 107 (10) :1165-1173